Table 2

 Log MAR visual acuity and vision-related quality of life before enrolment in study and 3 months after systemic immunosuppression

Baseline n (%)3 months n (%)
VA, visual acuity; VCM1, vision core module 1.
VA—worse eye
    0–0.2812 (32)20 (54)
    0.3–0.587 (19)5 (14)
    0.6–0.785 (14)1 (3)
    0.8–12 (5)5 (14)
    >111 (30)6 (16)
VA—better eye
    0–0.2825 (68)29 (78)
    0.3–0.587 (19)6 (16)
    0.6–0.782 (5)1 (3)
    0.8–13 (8)1 (3)
    >10 (0)0 (0)
VCM1 score
    0–19 (24)20 (54)
    1.1–213 (35)7 (19)
    2.1–311 (30)9 (24)
    3.1–44 (11)1 (3)
    4.1–50 (0)0 (0)